Claudio R. Alarcón is an Associate Professor in Pharmacology at Yale University School of Medicine. His research focuses on RNA metabolism's role in development, health, and disease, particularly RNA modifications and non-coding RNAs. He joined Yale in 2017 after postdoctoral training at The Rockefeller University and holds a PhD from Cornell University (2009) and a BSc from Pontificia Universidad Católica de Chile (1999). Research Interests: Functional roles of m6A RNA modifications MicroRNA biogenesis and cancer progression Non-coding RNA regulation in metastasis Key Appointments: Primary Faculty, Yale Cancer Biology Institute Member, Yale Cancer Center Faculty, Yale Combined Program in Biological and Biomedical Sciences His lab integrates bioinformatics, molecular, and cellular approaches to study cancer metastasis mechanisms, including miRNA processing disruptions and SOX4/TMEM2 pathways linked to clinical outcomes.
Michael Boutros is a Full Professor at Heidelberg University and Head of Division at the German Cancer Research Center (DKFZ). He currently serves as Dean of the Medical Faculty at Heidelberg University (since 2023) and Director of the Marsilius Kolleg (since 2020). He has held leadership roles including Coordinator of the Functional and Structural Genomics Program at DKFZ (2014–2023) and Acting Scientific Director (2015–2016). His academic base is within the Medical Faculty, focusing on molecular oncology and functional genomics. PhD, Witten/Herdecke University (1993–1996) Postdoctoral Research, Harvard Medical School (1999–2003) MPA, John F. Kennedy School of Government, Harvard University (1999–2001) Additional training: Cold Spring Harbor Laboratory, SUNY Stony Brook His research centers on Wnt signaling, functional genomics, and cancer pathways. He leads major research initiatives such as CRC 1324 on Wnt signaling and the ERC Synergy Grant DECODE. His work integrates high-throughput screening, CRISPR, and systems biology to dissect signaling networks in cancer and development. He has pioneered genome-wide RNAi and CRISPR screens to identify novel regulators of Wnt signaling across models. The 15 most recent articles reflect a strong focus on Wnt pathway regulation using functional genomics in both Drosophila and mammalian systems. Themes include high-throughput screening, CRISPR-based validation, cross-species conservation, and therapeutic targeting. Keywords span Cancer Biology, Systems Biology, and Signal Transduction, with subfields like RNAi, ubiquitination, stem cell regulation, and machine learning in image analysis. Michael Boutros has received numerous scientific honors: Elected member, Leopoldina National Academy of Sciences (2022) Elected member, Heidelberg Academy of Sciences (2022) EMBO Member (2013) ERC Advanced Grant (2012) Johann-Georg Zimmermann Research Award (2007) EMBO Young Investigator (2005) Member, 'Die Junge Akademie' (2003) He has been a recipient of the Emmy-Noether Program, McCloy Fellowship, Boehringer Ingelheim PhD Fellowship, Studienstiftung Fellowship, and Fulbright Fellowship. As a mentor and research leader, he has supervised numerous early-career scientists and coordinated large collaborative grants including the FP7 'CancerPathways' project. He currently serves as Speaker of the Research and Strategy Commission at Heidelberg University and Managing Director of the Health and Life Science Alliance Heidelberg Mannheim. He leads the CRC 1324 on Wnt signaling and is Coordinating PI of the ERC Synergy Grant DECODE. He is also Spokesperson of DFG Research Group 1036 and Coordinator of the former FP7 Coordinated Project 'CancerPathways'. His lab employs cutting-edge functional genomics tools to decode signaling networks in cancer and development.
Miler T. Lee is an Associate Professor at the University of Pittsburgh , focusing on gene regulation during early embryonic development through high-throughput experimental and computational genomics. He earned his Ph.D. in Genomics and Computational Biology in 2009 from the University of Pennsylvania under Dr. Junhyong Kim, followed by postdoctoral work with Dr. Antonio Giraldez at Yale University. Joining the university in 2016, his research spans maternal-to-zygotic transition (MZT), RNA stability, pluripotency networks, and evolutionary developmental biology, utilizing model organisms like zebrafish, Xenopus, and Hydractinia symbiolongicarpus. Key Research Themes: Maternally inherited RNA dynamics during embryogenesis Mechanisms of RNA degradation and transcriptome remodeling Evolution of pluripotency networks in hybrid species Role of zinc signaling in fertilization barriers Computational tools for RNA regulation and sensing Scientific Awards: Pan-American Society for Evolutionary Developmental Biology Junior Faculty Award (2024) Outstanding New Investigator – International Xenopus Board (2023) Basil O'Connor Scholar – March of Dimes (2017-2019) Recent publications highlight his work on enhancer classification, RNA degradation mechanisms, and cross-species MZT comparisons. His lab develops innovative methods like RESA for regulatory sequence analysis and studies evolutionary divergence in RNA localization patterns. While the articles span computational and experimental approaches, they consistently address RNA's role in cellular identity, developmental timing, and evolutionary adaptation. Applications include understanding pluripotency, designing RNA biosensors, and elucidating fertilization barriers. Prospective Ph.D. students are encouraged to contact him for opportunities in gene regulation, development, evo-devo, and computational genomics.
Brian D. Gregory is a Professor of Biology at the University of Pennsylvania's School of Arts & Sciences. His research focuses on RNA modifications, computational biology, and plant genetics, particularly studying how RNA modifications regulate gene expression in plants and animals. He holds a Ph.D. from Harvard University (2005) and a B.S.A. from the University of Arizona (2000). Research Interests: RNA epitranscriptomics (e.g., m6A, NAD+ caps) RNA secondary structure and protein interactions Genomic approaches to study plant stress responses Development of high-throughput sequencing tools like PIP-seq Recent Work Highlights: Recent studies include analyzing pathogen-induced RNA modifications' role in plant immunity (Plant Cell 2023), global RNA structure/protein interaction mapping, and epitranscriptomic dynamics in drought tolerance. His lab's work bridges computational methods with molecular genetics to uncover post-transcriptional regulatory mechanisms. Lab & Collaborations: The Gregory Lab uses Arabidopsis thaliana as a primary model organism but also explores animal systems. They collaborate with institutions like Cornell University and have developed protocols published in Current Protocols in Molecular Biology. Teaching: BIOL 4231: Genome Sciences and Genomic Medicine BIOL 6010: Communication for Biologists
Dr Amin Ardestani , Senior Lecturer in Metabolic Signaling at the Biomedical Institute for Multimorbidity (BIM), Hull York Medical School (HYMS) , specializes in unraveling molecular mechanisms of pancreatic β-cell failure in diabetes. His research program identifies novel therapeutic targets through signal transduction studies in metabolic disorders. Bachelor's in Biology, Tarbiat Moalem University (2004) Master's in Biochemistry, Institute of Biochemistry and Biophysics (2007) PhD in Biology, University of Bremen (2013) Junior Group Leader at University of Bremen (2014-2023) Research focuses on Hippo and mTOR signaling pathways in β-cell biology, autoimmunity, and regeneration. His work bridges mechanistic biology with drug discovery for diabetes, with significant findings on PHLPP1/2 phosphatases and MST1/2 kinases. Recent publications highlight therapeutic strategies for β-cell protection , including small molecule inhibitors (e.g., MST1/2 inhibitors) and metabolic enzyme modulation (LDHA). Collaborative studies explore SARS-CoV-2 interactions with pancreatic cells and cross-talk between acinar and β-cells in diabetes. 2019 JDRF Advanced Postdoctoral Fellowship 2018 Impulse grant & Career Advancement Award 2017 Early Investigators awards (Endocrine Society, EFSD/Lilly Programme) 2014 Albert Renold Fellowship & Bremer Studienpreis Professional roles include Editorial Board Member at Scientific Reports and Associate Editor at Frontiers in Endocrinology . He reviews grants for DFG, Diabetes UK, and ISF, and evaluates manuscripts for top-tier journals like Cell Metabolism and Nature Communications.
Katherine E. Varley, PhD is a Huntsman Cancer Institute Investigator and Associate Professor in the Department of Oncological Sciences at the University of Utah. She leads the Varley Lab and is a member of the Nuclear Control of Cell Growth and Differentiation Program, focusing on breast cancer genomics, epigenetics, and biomarker discovery. Her work bridges computational biology with clinical applications to improve breast cancer diagnosis and treatment. Dr. Varley earned her BS in Biology with a concentration in Computational Biology from Cornell University in 2003, followed by a PhD in Computational Biology from Washington University School of Medicine in 2009 under Dr. Robi Mitra. Her postdoctoral training was conducted in Dr. Richard M. Myers' laboratory at the HudsonAlpha Institute for Biotechnology, where she participated in the ENCODE Project Consortium. Her research focuses on using next-generation sequencing and computational analysis to study gene expression, transcription factor binding, and DNA methylation patterns in breast cancer. The Varley Lab investigates epigenetic gene regulation, develops novel molecular methods and bioinformatics approaches, and translates discoveries into clinical tools. Key research areas include Clinical Trial Genomics, Epigenome Engineering, Detecting Circulating Tumor DNA, and identifying Transcription Factors Driving Metastasis, with particular emphasis on triple-negative breast cancer. Analysis of Dr. Varley's publications reveals a consistent trajectory from fundamental genomic mechanisms to clinical translation, with recent work emphasizing biomarker discovery, tumor heterogeneity, and the development of genomic tools for precision oncology. Her research spans cancer biology, genomics, and computational analysis to address critical challenges in breast cancer treatment. Dr. Varley holds multiple patents related to cancer diagnostics and genomic technologies, including targeted sequencing methods, multigene assays for recurrence risk, and biomarkers for triple-negative breast cancer. These inventions reflect her commitment to translating basic research into clinical applications. She actively collaborates with clinical investigators in breast cancer trials and works closely with the Breast and Gynecologic Cancers Disease Center at Huntsman Cancer Institute. Her lab maintains four main research thrusts that collectively address breast cancer from molecular mechanisms to clinical applications, demonstrating a comprehensive approach to improving patient outcomes through genomic technologies.
Professor Susan Brooks is a faculty member at Oxford Brookes University in the School of Biological and Medical Sciences . Her research focuses on glycobiology , cancer progression , and the role of extracellular vesicles in metastasis. Professor of Cell Biology Director of Researcher Development Focus on breast and ovarian cancer Specialized in glycosylation mechanisms Research Interests : Dr. Brooks' work explores how aberrant glycosylation of proteins and glycans influences cancer cell behavior, including metastasis and drug resistance . Her recent studies examine extracellular vesicles as diagnostic tools and therapeutic targets. Article Trends : Over 25 years, Dr. Brooks has published 15+ articles on glycosylation patterns in breast and ovarian cancer. Key areas include lectin binding , miRNA regulation , and radiation-induced metastatic changes . Her work bridges cell biology and clinical applications .
Nikolaus Rajewsky is a leading Professor at the Max Delbrück Center for Molecular Medicine (MDC) and Charité – Universitätsmedizin Berlin , where he founded and directs the Berlin Institute for Medical Systems Biology (BIMSB) . His lab integrates experimental (biochemistry, molecular biology) and computational (bioinformatics, physics) approaches to study RNA regulation in gene expression , with applications to developmental biology, regeneration, neurodegenerative diseases, and cancer . Using model systems like C. elegans , planaria, and human brain organoids, his team pioneers cutting-edge methods such as MirDeep , DistMap , and FLAM-seq for RNA analysis. His research focuses on single-cell transcriptomics , spatial RNA sequencing , and circular RNA (circRNA) regulation , revealing novel roles for circRNAs like CDR1as in neuropsychiatric disorders. Recent work includes 3D tumor microenvironment mapping and computational modeling of RNA metabolism in diseases. Scientific Awards : Gottfried Wilhelm Leibniz Prize (2012) EMBO Membership (2010) Honorary PhD, Sapienza University of Rome (2014) Berlin Science Award (2009) His team's recent articles highlight breakthroughs in 3D spatial transcriptomics , circRNA degradation mechanisms , and mitochondrial disease modeling using human brain organoids. The lab actively collaborates with clinical partners across Charité and European institutions, driving the LifeTime initiative for cell-based interceptive medicine.
Prof. Dr. Jörg Hackermüller is a computational biologist with expertise in Omics data integration Toxicology Environmental risk assessment Non-coding RNA biology . He serves as Head of the Department of Computational Biology and Chemistry at the Helmholtz Centre for Environmental Research (UFZ) since 2024 and holds a Professorship at the Faculty of Mathematics and Computer Science at Leipzig University since 2021. His research focuses on Developing AI methods for chemical toxicity prediction Multi-omics integration for mechanistic toxicology Data standardization in environmental monitoring Non-coding RNAs as biomarkers in disease and toxicity and has produced 15+ recent publications spanning tools like multiGSEA and deepFPlearn+ . He collaborates with teams across UFZ Leipzig University Novartis Fraunhofer Institute and leads projects like InCeTo and SafePol , integrating exposome research with systems biology.
Norbert O. Reich is a Distinguished Professor in the Department of Chemistry & Biochemistry at the University of California, Santa Barbara (UCSB), affiliated with the College of Letters and Science. He joined UCSB in 1987 after completing his Ph.D. at UCSF in 1984 and an NIH postdoctoral fellowship there. His research focuses on enzyme mechanisms, particularly DNA methylation and telomerase, with applications in antibiotic and cancer therapy design. He also develops innovative chemical biology tools, including gold nanoshell-based drug delivery systems and fluorescence-based protein tracking methods. Education: Ph.D. in Chemistry from UCSF (1984). Awards: Regent's Junior Faculty Fellowship (1987), American Cancer Society Faculty Research Award (1991), UC President's Award for Excellence in Undergraduate Research (1994). Research Interests: Epigenetic regulation via DNA methylation in bacteria and mammals Enzyme mechanisms of DNA methyltransferases (e.g., DNMT3A, CcrM) Design of therapeutic inhibitors targeting epigenetic enzymes Light-controlled delivery of proteins/RNA via gold nanoshells Protein-DNA interaction analysis using microfluidic arrays Awards and Recognition: His honors reflect contributions to both research and education, emphasizing his dual impact in science and teaching. Lab and Collaborations: Leads the Reich Lab, collaborating with researchers like Tom Pettus (UCSB) and Erkki Ruoslahti. Projects include antibiotic development, cancer epigenetics, and nanotechnology-driven drug delivery. Future Work: Expanding applications of nanoshell technology for targeted gene silencing and exploring allosteric inhibitors of DNMT3A for cancer treatment.
James Manley is the Julian Clarence Levi Professor of the Life Sciences at Columbia University, with extensive research in gene expression regulation. His work spans transcription, RNA splicing, and polyadenylation mechanisms in human cells, connecting these processes to neurodegenerative diseases (ALS/FTD) and cancers. Affiliation: Columbia University, Department of Biological Sciences Contact: jlm2@columbia.edu Research Interests: Dr. Manley's laboratory investigates nuclear processes including: Transcriptional control via RNA polymerase II CTD modifications Alternative splicing regulation by hnRNP and SR proteins Polyadenylation dynamics in cell cycle and differentiation Disease mechanisms in spliceosome mutations (SF3B1, SRSF2) RNA-protein interactions in stress responses Publication Trends: Recent work focuses on disease-associated mutations affecting RNA processing, non-canonical RNA functions, and immune regulation via polyadenylation. Articles span molecular oncology, neurodegeneration, and RNA surveillance mechanisms. Scientific Recognition: Member, American Academy of Arts & Sciences Member, National Academy of Sciences Key Collaborations: Studies involve interdisciplinary work with neurology, cancer biology, and immunology teams. His lab employs biochemical assays, structural analysis, and genetic models to dissect RNA processing pathways.
Guillaume Chanfreau is a Professor in the Department of Chemistry and Biochemistry within the College of Letters and Science at the University of California Los Angeles (UCLA). His research focuses on fundamental mechanisms of RNA metabolism, with particular emphasis on RNA splicing, decay pathways, and ribonuclease functions. His work spans molecular biology, biochemistry, and genetics, utilizing yeast as a primary model organism to investigate conserved RNA processing mechanisms. Professor Chanfreau's research interests center on understanding how RNA processing pathways regulate gene expression. His work examines transcription termination, RNA splicing fidelity, RNA decay mechanisms, and the role of ribonucleases in cellular RNA homeostasis. He investigates how these processes are interconnected and how they respond to cellular stress conditions. His laboratory has made significant contributions to understanding how RNA quality control mechanisms prevent the accumulation of aberrant transcripts and maintain cellular health. Analysis of Chanfreau's recent publications (2020-2025) reveals a strong focus on RNA splicing mechanisms, RNA decay pathways, and ribonuclease functions. His work frequently employs yeast genetics combined with advanced RNA sequencing techniques. A notable trend is the increasing use of long-read sequencing technologies to analyze RNA isoforms and decay intermediates. His research consistently bridges fundamental molecular mechanisms with potential implications for understanding human diseases related to RNA processing defects. Professor Chanfreau has been continuously funded by the National Institutes of Health, with his current grant R35GM130370 (2019-2023) titled 'The Control of Gene Expression by Eukaryotic Ribonucleases' and previous long-term funding through R01GM061518 (2000-2019). His research program has supported numerous graduate students and postdoctoral researchers who have contributed to his extensive publication record spanning over two decades.
Prof. Valentina Boeva is an Assistant Professor at the Department of Computer Science, ETH Zürich, specializing in biomedical informatics. Her research focuses on integrating machine learning and computational methods to address challenges in genomics, oncology, and precision medicine. She holds a position in the Professur für Biomedizininformatik (Biomedical Informatics) and is based at CAB G32.2, Universitätstrasse 6, Zürich, Switzerland. Her work emphasizes applications such as cancer biomarker discovery, tumor heterogeneity analysis, and epigenetic profiling. She teaches courses including Machine Learning Seminar, Data Science Lab, and Machine Learning for Genomics. Her research group develops computational tools like CDState and UniversalEPI to decode complex biological systems. She actively publishes in top-tier journals, with recent work on exosome-driven diagnostics and chromatin interaction modeling. Her scientific contributions span methodologies for single-cell data analysis, survival modeling, and drug response prediction. She collaborates across disciplines to bridge computational science with clinical applications in cancer research.
Nadya Dimitrova is an Assistant Professor in the Department of Molecular, Cellular, and Developmental Biology at Yale University, affiliated with the Yale School of Medicine. She holds secondary appointments in Genetics and is a member of multiple interdisciplinary centers, including the Center for RNA Science and Medicine. Her research focuses on long non-coding RNAs (lncRNAs) and their roles in cancer biology, particularly in tumor suppression and oncogenesis. Dimitrova earned her Sc.B. in Biochemistry from Brown University (2002), a Ph.D. from The Rockefeller University (2009), and completed postdoctoral training at MIT's Koch Institute. Notable awards include the HHMI Predoctoral Fellowship, Damon Runyon Postdoctoral Fellowship, and the 2023 Yale Cancer Center Class of '61 Award. Her lab explores lncRNA mechanisms using genomic and genetic tools, aiming to uncover their roles in cancer pathways. Recent work highlights lncRNAs' roles in metastasis, cardiac hypertrophy, and p53 signaling. Collaborations with researchers like Antariksh Tyagi and Clara Liao drive translational insights into RNA-based therapies. Education: Sc.B., Brown University (2002); Ph.D., The Rockefeller University (2009). Research interests include lncRNA regulation, cancer transcriptomics, and RNA-driven disease mechanisms. Her lab integrates systems biology approaches to dissect lncRNA functions in health and disease.
James Smith is an Associate Professor and scientific group leader at Norwich Medical School, University of East Anglia, UK, where he leads research in pluripotent stem cells and cardiovascular disease. He is a member of the Metabolic Health and Cardiovascular and Metabolic Health research groups. Education: PhD in Mesenchymal Stem Cells and Extracellular Matrix, University of Birmingham Post-doctoral training in automated manufacture of human pluripotent stem cells, University of Nottingham His research focuses on using CRISPR gene editing and human induced pluripotent stem cells (hiPSCs) to model and investigate cardiovascular diseases. Key areas include the role of snoRNAs in heart development and disease, cardiomyocyte maturation, and inflammatory responses following cardiac interventions. He established his independent research group at UEA in 2019. The recent publications reflect a strong trend in molecular and cellular cardiology, particularly in non-coding RNA biology, extracellular matrix interactions, and stem cell-based disease modeling. His work bridges basic science with clinical implications, especially in hypertrophic cardiomyopathy and post-intervention inflammation. Scientific Funding & Projects: Identifying novel SNORD116 targets and signalling pathways – Foundation for Prader-Willi Research (2025–2026) Do snoRNAs govern genotype-phenotype interactions in hypertrophic cardiomyopathy? – British Heart Foundation (2023–2027) Dupuytren’s Disease: Genetic variants and cellular phenotype – Action Arthritis (2026–2029) Investigating cardiomyocyte communication in hypertrophic cardiomyopathy – Academy of Medical Sciences (2020–2022) He advises graduate students and early-career researchers in his lab, though specific names are not listed. He has secured competitive grants from major funding bodies and maintains an active laboratory focused on translational cardiovascular research. His work contributes to the UN Sustainable Development Goal 3: Good Health and Well-being. He is based at the Bob Champion Research & Education Building and maintains a lab website at https://www.smithlabuea.com/ .
